


COSENTYX™ TARGETS IL-17A: A NEW WAY TO TREAT INFLAMMATORY SPINAL AND JOINT DISEASES

HOW COSENTYX WORKS TO BLOCK IL-17A¹⁻⁸



COSENTYX BRINGS RAPID AND LONG-TERM RELIEF OF THE SIGNS AND SYMPTOMS OF PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS, TWO OF THE MOST COMMON INFLAMMATORY JOINT DISEASES^{2,9-16}



Skin & Nails



Joints & Tendons



Toes & Fingers



Spine



Pelvis



Neck

Psoriatic arthritis causes psoriasis, painful tendons and swelling of the joints, toes and fingers.

Ankylosing spondylitis causes inflammation of the spine, pelvis and neck leading to irreversible damage and disability. It can also cause spinal fusion.

COSENTYX: TREATING INFLAMMATORY DISEASES AT THEIR CORE

Cosentyx is the first of a new type of treatment targeting IL-17A to show rapid and long-term benefits in patients with psoriatic arthritis and ankylosing spondylitis⁹⁻¹⁵

References

¹Weaver CT, et al. Annu Rev Immunol. 2007;25:821-52. ²American College of Rheumatology (ACR) website. Accessed October 2014. ³Van Baarsen LGM, et al. Ann Rheum Dis. 2011;70:A79. ⁴Van Kuijk A and Tak P. Curr Rheumatol Rep. 2011;13(4):353-59. ⁵Leipe J, et al. Arthritis Rheum. 2010;62(10):2876-85. ⁶Noordenbos T, et al. Arthritis Rheum. 2012;64:99-109. ⁷Taylan A, et al. Rheumatol Int. 2012;32:2511-2515. ⁸Huppertz, C, et al. The Anti-IL-17A Monoclonal Antibody Secukinumab (AIN457) Inhibits Pro-Inflammatory Mediator Release From Human Primary Synoviocytes Costimulated With IL-17 and TNF. [abstract]. Arthritis Rheum 2013;65 Suppl 10 :951⁹Gladman DD, et al. Ann Rheum Dis. 2005;64:ii14-ii17. ¹⁰Lee Set al. P T. 2010;35(12): 680-689. ¹¹Sieper J et al. Ann Rheum Dis. 2002;61(Suppl III):iii8-iii18. ¹²Lories R. Nat Rev Rheumatol. 2011;7:700-707. ¹³Barkham N, et al. Rheum. 2005;44:1277-1281. ¹⁴Sieper J, et al. ACR/ARHP Annual Meeting, Boston, MA, USA, 2014. ¹⁵Mease, et al. The Lancet. 2015, 386, No. 9999; p1137-1146. ¹⁶Arthritis Research UK website. Accessed October 2015.